Status:
UNKNOWN
Haploidentical Stem Cell Transplantation in Neuroblastoma
Lead Sponsor:
Lund University Hospital
Conditions:
Neuroblastoma
Eligibility:
All Genders
6-21 years
Phase:
EARLY_PHASE1
Brief Summary
Children with primary resistant or relapsed neuroblastoma who do not achieve remission with conventional chemotherapy have extremely dismal prognosis. A novel treatment strategy combining tumor target...
Eligibility Criteria
Inclusion
- Refractory neuroblastoma (any chemo/radiosensitive stable disease)
- Relapse incl. autologous HSCT 3 m earlier
- Primary induction failure
- Cardiac output SF ≥25%
- Creatinine clearance ≥40 cc/min/1.73 m2
- Performance score of ≥50% (Lansky or Karnofsky)
- Available haploidentical family donor, aged ≥18 yrs, HIV-neg
Exclusion
- Rapidly progressive disease
- Pregnancy
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00790413
Start Date
August 1 2005
End Date
December 31 2022
Last Update
February 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lund University Hospital, Department of Pediatric Oncology and Bone Marrow Transplantation
Lund, Sweden, 221 85